Project Grant RF1AG078335
Award Date
9/1/23
Completion Date
8/31/26
Dollars Obligated
$2.2M
Federal Agency
National Institute on Aging
Federal Grant Program
93.866
Assistance Type
Project Grant
Place of Performance
Seattle, WA 98108, USA
Similar Awards
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) to Jillion Therapeutics Inc. aims to identify small molecule compounds that can bind to and modify the biological behavior of tau protein, which is implicated in Alzheimer's disease and other neurodegenerative "tauopathies". The $496,373 award, spanning September 2024 to August 2025, will utilize the company's DNA-encoded library (DEL) drug discovery platform to screen a large chemical...
This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) is providing $2,836,419 to the Seattle Institute for Biomedical and Clinical Research to investigate how the SUT-6/NIPP1 protein regulates pathological tau in Alzheimer's disease and other neurodegenerative "tauopathy" conditions. The key objectives are to: 1) define the functions of SUT-6/NIPP1 important for suppressing tau toxicity in a C. elegans model, 2) identify downstream...
This $519,750 Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) supports a 2-year research study by the J. David Gladstone Institutes, a non-profit biomedical research organization in San Francisco. The study aims to explore the underlying molecular mechanisms by which reducing levels of the tau protein can prevent or diminish excitation/inhibition imbalance and network hyperexcitability in the brain. This imbalance has been observed in various...
The National Institute on Aging (NIA) awarded a 3-year, $4,618,216 Cooperative Agreement (CFDA 93.866 - Aging Research) to the University of California, San Diego (UC San Diego) to develop a novel microtubule-stabilizing drug candidate, CNDR-51997, for the treatment of Alzheimer's disease and related neurodegenerative "tauopathy" conditions. The primary objectives are to advance CNDR-51997 through IND-enabling studies and submit an Investigational New Drug (IND) application to the FDA....
This Project Grant award, with a total funding amount of $431,750, was provided by the National Institute on Aging (NIA) under the Aging Research federal grant program (CFDA 93.866). The award is for the development and evaluation of a novel immuno-gene therapy approach using a single-chain fragment variable (scFv) derived from an anti-tau oligomeric complex 1 (TOC1) antibody. The key objectives are to: 1) generate and validate the TOC1-scFv-HaloTag-Proteasome Degradation Signal (PDS)...
This $1,592,854 federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) will support research by the University of Illinois to understand the biological mechanisms underlying neurodegenerative tauopathy diseases, including Alzheimer's disease. The project aims to define how modifications to the tau protein, such as phosphorylation and other post-translational changes, can disrupt its normal scaffolding functions and lead to the dysregulation of critical...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $1,100,000 to the University of Texas Medical Branch at Galveston to investigate the mechanisms of pathological tau protein spreading in Alzheimer's disease. The project aims to determine how amyloid-beta oligomers modulate the binding and internalization of toxic tau oligomers at vulnerable synapses, a key process underlying the spatiotemporal progression of tau pathology in the central nervous...
This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $437,250 to the University of California, San Diego (UCSD) to develop new tools to image the tau protein and its role in Alzheimer's disease. The goal is to create a peptide-based probe that can measure tau in its different forms - soluble, liquid-liquid phase separation, and liquid-solid phase separation - within living cells using aggregation-induced emission (AIE) technology. This...
This $1,147,300 Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) will support research by Wayne State University to investigate how pathogenic forms of the tau protein interfere with dendritic protein synthesis and contribute to synaptic dysfunction in Alzheimer's disease. The research aims to enrich the understanding of how tau pathology leads to early synaptic alterations in Alzheimer's, with the goal of identifying molecular targets for intervention...
This $1,823,353 Project Grant awarded by the National Institute on Aging (CFDA 93.866 Aging Research) to the Seattle Institute For Biomedical And Clinical Research aims to elucidate the molecular mechanisms by which pathological tau protein causes neurodegeneration in Alzheimer's disease (AD) and related tauopathy disorders. The research project will leverage a C. elegans model of tauopathy to investigate the functional role of nuclear speckles, membraneless organelles involved in RNA...